Gold prices steady ahead of Fed decision; weekly weakness noted
In a turbulent market environment, Cellectis S.A. (NASDAQ:CLLS) stock has reached a 52-week low, trading at $1.24. According to InvestingPro analysis, the stock’s RSI indicates oversold conditions, while the company maintains a healthy balance sheet with more cash than debt. The French biopharmaceutical company, which specializes in developing immunotherapies based on gene-edited T-cells, has seen its shares plummet as investors navigate through a series of industry-wide setbacks and economic headwinds. Despite the challenging environment, the company achieved impressive revenue growth of 47% in the last twelve months, maintaining a strong gross margin of 98%. Over the past year, Cellectis has experienced a significant downturn in its stock value, with a 1-year change showing a stark 50% decrease. This latest price level reflects investor concerns over the company’s pipeline progress and the broader market’s appetite for risk in the biotech sector. InvestingPro analysis suggests the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report, which offers deep-dive analysis of over 1,400 US equities.
In other recent news, Cibus Inc. has successfully secured approximately $22.6 million through a registered direct offering. This transaction includes the sale of 9,040,000 shares of Class A common stock, with pre-funded warrants and equal warrants to purchase additional shares, each priced at $2.50. The offering is expected to close around January 24, 2025, subject to customary conditions. The company plans to use the net proceeds to advance its pipeline of productivity traits and meet general corporate needs while seeking long-term financing. The warrants have a five-year lifespan and a $2.50 exercise price, becoming exercisable after stockholder approval. A.G.P./Alliance Global Partners (NYSE:GLP) is serving as the sole placement agent for the offering. Additionally, the offering includes amendments to existing Investor Warrants, reducing their exercise price to $2.50 per share and extending their termination date. These developments are part of Cibus’s efforts to enhance its gene-editing technology and expand its presence in agricultural innovation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.